BeOne Medicines AG

Q2 revenue was $1.7 billion, up 30% year over year. GAAP diluted EPS was $2.05 per ADS versus $0.84 a year ago, and net income was $237 million, including an approximately $60 million impact from a previously disclosed tax audit settlement. Gross profit was $1.5 billion with gross margin just under 90%; operating income was $325 million; adjusted operating income was $503 million, adjusted EPS was $3.84 versus $2.25, and free cash flow was $435 million, doubling from the prior-year period. For 2026, BeOne raised revenue guidance to $6.6 billion-$6.8 billion, expects gross margin to remain in the high 80% range, updated operating expenses to $4.8 billion-$5.0 billion, and now expects GAAP operating income of $1.0 billion-$1.1 billion and non-GAAP operating income of $1.7 billion-$1.8 billion.

John Oyler framed Q2 as a strong quarter across the business, emphasizing that BeOne is benefiting from both a durable commercial engine and an increasingly broad pipeline. He highlighted BRUKINSA’s continued momentum, the FDA approval of BEQALZI, and the MANGROVE result as evidence that BeOne’s hematology strategy is working, while also pointing to solid-tumor programs moving toward registrational development. His tone was notably confident, saying the company is “never been better positioned,” while still acknowledging there is “a lot of work ahead.”

Aaron Rosenberg said the quarter reflected strong execution and a durable underlying business, with growth driven by BRUKINSA demand, a broad commercial base, and improving duration of therapy. He cited U.S. BRUKINSA sales of $893 million, TEVIMBRA sales of $229 million, the Amgen-licensed portfolio at $157 million, gross margin just under 90%, and free cash flow of $435 million. On guidance, he raised revenue by $300 million to $6.6 billion-$6.8 billion, kept gross margin in the high 80% range, and lifted GAAP operating income by $250 million to $1.0 billion-$1.1 billion while noting continued investment in commercial execution and pipeline advancement.

Analysts pressed on BRUKINSA’s growth drivers, asking how much came from non-CLL indications and whether Acala ven was affecting U.S. dynamics; management said they are not seeing much impact from AV AMPLIFY yet and that growth is coming from strong demand across indications, with non-CLL indications making up about one-third of prevalence and contributing above their weight. On CELESTIAL-301, management said they remain confident in the PFS endpoint despite the uMRD analysis not showing superiority, and they do not have hazard-ratio details because the company remains unblinded. Questions on MANGROVE brought positive physician feedback, with management saying experts were excited about a chemo-free frontline MCL option; on tacabrutideg, management said the program remains on track for a potential accelerated approval submission in Q4 and that the Phase III comparator study versus pirtobrutinib is enrolling well.